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Abstract
Background: Fabry disease is an X-linked lysosomal storage disorder that results from a deficiency of the enzyme
α-galactosidase A. Fabry disease is present in 4–5% of men with unexplained left ventricular hypertrophy or
cryptogenic stroke. As enzyme replacement therapy is now more widely available, it is important to recognise the
signs and symptoms of the disease and establish the diagnosis so that early treatment can be started before
irreversible organ damage occurs.
Case Presentation: A previously fit and well 32-year-old Caucasian male presented with multisystem dysfunction
including renal impairment. Although he had no suggestive symptoms, a diagnosis of Fabry disease was first
established on a native renal biopsy. This was confirmed by enzymatic testing and subsequent genetic analysis that
revealed a potentially new pathogenic variant.
Conclusions: This case highlights the importance both of Fabry disease as a differential diagnosis in patients with
renal impairment in the context of multi-system disease and also of adequate tissue sampling for electron
microscopy when performing native renal biopsies.
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Background
Fabry disease is a rare x-linked lysosomal storage dis-
order. However, with new diagnostic techniques it is
being increasingly recognised as a cause of end-stage
renal disease. With the emergence of enzyme replacement
therapies, early diagnosis of this multisystem disease is cru-
cial. We describe a patient who presented with non-specific
symptoms whose diagnosis of Fabry disease was established
on a native renal biopsy.
Case Presentation
A 32-year-old Caucasian male presented with a three-
week history of fever, abdominal pain, cough and exer-
tional breathlessness after a recent trip to Turkey. He
had been previously entirely healthy with no significant
family history of note and was taking neither regular nor
recently prescribed medications. He had no history of
hypertension and his haemodynamic parameters remained
normal throughout his admission. Investigations revealed:
a white cell count of 13.8 x109/L; C-reactive protein of
278 mg/L; alanine transaminase of 468 units/L; serum
albumin of 30 g/L and a serum creatinine of 535 μmol/L.
There was evidence of haematoproteinura on dipstick
urinalysis with a protein to creatinine ratio of 285 (normal
range <30). A chest x-ray showed no evidence of consoli-
dation, but revealed significant cardiomegaly. A subse-
quent echocardiogram revealed a bright echotexture to
the myocardium and confirmed the presence of a 4 cm
global pericardial effusion causing right atrial collapse,
the cardinal sign of cardiac tamponade (Figure 1). An
ultrasound scan of his abdomen demonstrated spleno-
megaly without hepatomegaly, and kidneys of normal
echotexture, the right measuring 9 cm and the left
10.3 cm. A nephritis screen including serum ANA,
ANCA, complement levels and immunoglobulins was
unremarkable.
He was treated initially for an atypical infection with
appropriate broad-spectrum antibiotic cover with a cor-
responding improvement in both white cell count and
CRP levels. The day after admission he underwent a
pericardiocentesis because of the risk of tamponade.
Subsequent histological examination of the pericardial
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fluid showed evidence of acute on chronic pericarditis
secondary to uraemia. All cultures of blood, urine and
pericardial fluid (including mycobacterium, leptospirosis
and mycoplasma) were negative. Despite these measures,
his creatinine continued to rise and a renal biopsy was
performed.
Light microscopy showed: very active tubulointerstitial
inflammation with lymphocytic and plasma cell infil-
trates as well as interstitial oedema related to his concur-
rent antibiotic treatment with intravenous co-amoxiclav
nd; global sclerosis of all 22 sampled glomeruli.
Toluidine blue staining revealed abundant deposition of
glycolipid inclusions within the podocyte (Figure 2a).
Immunofluorescence was negative. Electron microscopy
demonstrated the characteristic enlarged secondary
lysosomes (myeloid or ‘zebra’ bodies) packed with lamel-
lated membrane structures that are associated with
Fabry disease (Figure 2b). The diagnosis was later con-
firmed, initially by a blood spot α-galactosidase activity
of 3.61 pmol/spot/h (5.51-58.1) and subsequently by a
reduced plasma α-galactosidase A activity of 1.88 μmol/L/h
(3-20) as well as elevated levels of globotriaosylceramide
(Gb3) in the urine at 0.5 mg/mmol creatinine (0-0.03).
Genetic sequence analysis revealed a missense point muta-
tion causing the substitution of arginine with proline at
amino acid residue 356, consistent with a diagnosis of Fabry
disease.
On resolution of his sepsis, his C-reactive protein and
alanine transaminase levels returned to normal and a repeat
abdominal ultrasound confirmed that his splenomegaly had
Figure 1 Apical four-chamber ECHO demonstrating: a 3.5 cm pericardial effusion apically (at the cursor) and more than 4 cm around
the anterior wall; right atrial collapse from resulting tamponade and; although there was no evidence of left ventricular hypertrophy,
the highly echogenic myocardium is also typical of Fabry's.
Figure 2 Histological sections showing: a) toluidine blue staining demonstrating abundant deposition of glycolipid inclusions within
the podocytes and; b) electron microscopy with ‘zebra’ bodies - enlarged secondary lysosomes packed with lamellated membrane
structures.
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also resolved. Despite an initial improvement in serum cre-
atinine to 250 μmol/L after commencement of steroid ther-
apy for the underlying antibiotic-induced nephritis, he
became dialysis dependent after six months, although sub-
sequently received a living, non-related renal transplant
from his wife. He is now receiving enzyme replacement
therapy.
Interestingly, he had no symptoms suggestive of Fabry
disease. In particular there were no acroparathesiae,
gastrointestinal symptoms and no history of heat intoler-
ance; he described sweating normally on exertion. He
also denied any problems with his skin.
Discussion
Fabry disease is caused by mutations in the gene encod-
ing the lysosomal enzyme α-galactosidase A [1]. This
results in reduced or absent α-galactosidase A activity
and intra-lysosomal accumulation of neutral glycosphin-
golipids, mainly Gb3 (a substrate of α-galactosidase A),
in many cells including renal epithelial cells, endothelial
cells, vascular smooth muscle cells, cardiac myocytes
and neurons of the autonomic nervous system. As Gb3
is easily accessible in both plasma and urine and seems
to be directly involved in the renal pathology of Fabry
disease, it may be a potential diagnostic assay for
patients presenting with the classical disease phenotype
[2]. However, its exact utility in the diagnosis and prog-
nosis of Fabry remains contentious [3].
Interestingly, the genetic sequence analysis in this case
revealed a hemizygous mutation for a G to C transver-
sion at nucleotide 1067 (c.1067 G>C) in exon 7 of the
α-galactosidase A (GLA) gene. This variant is predicted
to result in the substitution of arginine with proline at
amino acid residue 356 (p. Arg356Pro). Although not
previously described in the literature, two mutations
have been reported in Fabry patients that cause substitu-
tion of the same Arg356 residue (p. Arg356Trp and p.
Arg356Gln) [4,5]. Both mutations produce small
amounts of residual enzyme (as in this case), but still at
levels that would cause disease. Therefore, in the context
of all the other clinical findings, this variant is consid-
ered to be pathogenic.
Estimates of the incidence of Fabry disease vary mark-
edly and although rare, it is likely to be more common
than originally thought. A newborn screening study in
Italy of more than 37,000 consecutive male neonates
demonstrated an incidence of α-galactosidase A defi-
ciency of 1 in 3100 [6]. In patients with end-stage renal
disease on haemodialysis, studies have reported a preva-
lence from anywhere between 0.33% up to 1.2% [7,8].
One potential reason that the condition is under-
recognised is that from the total number of cases of
Fabry patients diagnosed, nearly half of them (46%)
come from family screening [9]. This clearly demonstrates
how difficult it is to find new cases / families and empha-
sising that when a new index of Fabry is diagnosed,
screening the family is an important way of diagnosing
previously undetected disease.
In general, hemizygous males are more severely
affected than heterozygous females. In males, life expect-
ancy is reduced by an average of 20 years [10] and in
females by 15 years [11] with both being affected from
an early age [12]. Death usually occurs due to renal, car-
diovascular or cerebrovascular complications [1,10,11],
with renal dysfunction being the main cause of death in
men prior to the advent of renal failure requiring dialysis
or transplantation [9].
Fabry nephropathy is characterised by variable levels
of disease severity but with an overall rate of progression
of chronic kidney disease (CKD) very similar to diabetic
nephropathy, with evidence suggesting that all patients
living into their 50s with classical Fabry disease will de-
velop end-stage renal failure [9]. Accordingly, in addition
to the aggressive treatment of hypertension, renoprotec-
tive measures should be introduced as soon as hyperfil-
tration and/or microalbuminuria are detected. Two
enzyme replacement therapies (ERTs) have been shown
to be effective in halting the progression of renal mani-
festations in patients with mild or moderate Fabry
nephropathy and in slowing the progression of CKD in
patients with advanced disease. Significant proteinuria
and marked glomerulosclerosis (as with this patient) are
the best predictors of progression of Fabry nephropathy
despite ERT [13]. Consequently, ERT and nephroprotec-
tive measures should be started as soon as possible in
male patients with the disease [14].
Given the importance of early initiation of treatment,
timely and accurate diagnosis of Fabry disease is key.
With this patient, as there were no clues to the presence
of Fabry disease in the presentation, family history or
clinical findings, making the correct diagnosis unknow-
ingly rested on the interpretation of the needle biopsy.
In general, this is not usually difficult however in this
case which presented with advanced renal impairment;
all 22 of the glomeruli obtained for light microscopy
were globally sclerosed. Consequently the diagnosis
rested completely on tissue collected and processed for
EM. A semi-thin (0.5 μm) resin embedded survey sec-
tion was stained with Toluidine blue to check for the
presence of glomeruli before ultra thin sectioning for
transmission EM. These steps showed the characteristic
osmiophilic inclusions and Zebra bodies respectively
(see Figure 2). A second histopathologist and member of
the European Network of Fabry Pathologists confirmed
these findings. A recent survey suggests that only half of
institutions routinely collect tissue from native biopsies
specifically for EM [15], confounded by an inadequate
sampling rate. This case highlights the importance of
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EM in the evaluation of renal biopsies, underlining pre-
vious advice that this should be standard practice [16].
Indeed, in a review of laboratory practice in renal path-
ology, the evaluation of renal biopsy specimens without
electron microscopy was regarded as negligent [17].
Conclusion
In conclusion, this case highlights the importance both
of Fabry disease as a differential diagnosis in patients
with renal impairment in the context of multi-system
disease and also of adequate tissue sampling for EM
when performing native renal biopsies.
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